Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Merck
McKinsey
McKesson
Medtronic

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

NEUPOGEN Drug Profile

See Plans and Pricing

« Back to Dashboard

US Patents for NEUPOGEN

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial Bayer Intellectual Property GMBH (Monheim, DE) 2026-12-05 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial EnBio Limited (Dublin, IE) 2026-09-11 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial 2038-06-12 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial CARDIONOVUM Sp.z.o.o. (Warsaw, PL) 2031-09-29 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial Genentech, Inc. (South San Francisco, CA) 2038-05-29 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial GENMAB A/S (Copenhagen V, DK) 2030-06-09 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for NEUPOGEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C01562968/01 Switzerland   Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC 65183 17.12.2014
300687 Netherlands   Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928/001-002 20140527
C20100006 00032 Estonia   Start Trial PRODUCT NAME: REVOLADE-ELTROMBOPAG; REG NO/DATE: C(2010)1662 11.03.2010
CR 2014 00047 Denmark   Start Trial PRODUCT NAME: SILTUXIMAB; REG. NO/DATE: EU/1/14/928/001-002 20140527
C300687 Netherlands   Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928/001-002 20140522
C20140027 00115 Estonia   Start Trial PRODUCT NAME: SILTUKSIMAB;REG NO/DATE: K(2014)3557 (LOPLIK) 27.05.2014
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Merck
McKinsey
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.